Literature DB >> 32154591

The use of Mendelian randomisation to identify causal cancer risk factors: promise and limitations.

Harvinder Gala1, Ian Tomlinson1.   

Abstract

The use of observational analyses, such as classical epidemiological studies or randomised controlled trials (RCTs), to infer causality in cancer may be problematic due to both ethical reasons and technical issues, such as confounding variables and reverse causation. Mendelian randomisation (MR) is an epidemiological technique that uses genetic variants as proxies for exposures in an attempt to determine whether there is a causal link between an exposure and an outcome. Given that genetic variants are randomly assigned during meiosis according to Mendel's first and second laws of heritability, MR may be thought of as a 'natural' RCT and is therefore less vulnerable to the aforementioned problems. MR has the potential to help identify new, and validate or disprove previously implicated, modifiable risk factors in cancer, but it is not without limitations. This review provides a brief description of the history and principles of MR, as well as a guide to basic MR methodology. The bulk of the review then examines various limitations of MR in more detail, discussing some of the proposed solutions to these problems. The review ends with a brief section detailing the practical implementation of MR, with examples of its use in the study of cancer, and an assessment of its utility in identifying cancer predisposition traits.
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Entities:  

Keywords:  MR cancer; MR limitations; MR methodology; MR practical implementation; Mendelian randomisation; cancer predisposition

Year:  2020        PMID: 32154591     DOI: 10.1002/path.5421

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  4 in total

Review 1.  Review of Mendelian Randomization Studies on Endometrial Cancer.

Authors:  Jian-Zeng Guo; Qi-Jun Wu; Fang-Hua Liu; Chang Gao; Ting-Ting Gong; Gang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-09       Impact factor: 6.055

2.  Using Genetic Variants to Evaluate the Causal Effect of Plasma Phospholipid Fatty Acids on Breast Cancer and Prostate Cancer: A Mendelian Randomization Study.

Authors:  Ze Yang; Jingjia Li; Yandi Sun; Zihao Qu; Yindan Lin; Lihong Zhang; Qian He; Xueyao Jia; Mashaal Ahmad; Xueyun Zhang; Yan Luo
Journal:  Front Genet       Date:  2021-06-30       Impact factor: 4.599

3.  A modifiable risk factors atlas of lung cancer: A Mendelian randomization study.

Authors:  Jiayi Shen; Huaqiang Zhou; Jiaqing Liu; Yaxiong Zhang; Ting Zhou; Yunpeng Yang; Wenfeng Fang; Yan Huang; Li Zhang
Journal:  Cancer Med       Date:  2021-06-02       Impact factor: 4.452

4.  Systematic review of Mendelian randomization studies on risk of cancer.

Authors:  Georgios Markozannes; Afroditi Kanellopoulou; Olympia Dimopoulou; Dimitrios Kosmidis; Xiaomeng Zhang; Lijuan Wang; Evropi Theodoratou; Dipender Gill; Stephen Burgess; Konstantinos K Tsilidis
Journal:  BMC Med       Date:  2022-02-02       Impact factor: 11.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.